<DOC>
	<DOC>NCT01356888</DOC>
	<brief_summary>The purpose of this study is to compare the BIOTRONIK Orsiro Drug Eluting Stent System with the Abbott Xience Prime™ Drug Eluting Stent System with respect to in-stent Late Lumen Loss in a non-inferiority study in de novo coronary lesions at 9 months.</brief_summary>
	<brief_title>Study of the Orsiro Drug Eluting Stent System</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Main Subject has provided a written informed consent Single de novo lesion with ≥ 50% and &lt;100% stenosis in up to 2 coronary arteries The target lesion length is ≤ 26 mm The target reference vessel diameter is ≥ 2.25 mm and ≤ 4.0 mm Main Evidence of myocardial infarction within 72 hours prior to index procedure Unprotected left main coronary artery disease (stenosis &gt;50%) Threevessel coronary artery disease at time of procedure Thrombus in target vessel Target lesion involves a side branch &gt; 2.0 mm in diameter Heavily calcified lesion Target lesion is located in or supplied by an arterial or venous bypass graft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>